Crossmark

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Published Online: 2017-05-18

Published Print: 2017-12

Authors

Nägele, Virginie

Kratzer, Andrea

Zugmaier, Gerhard

Holland, Chris

Hijazi, Youssef

Topp, Max S.

Gökbuget, Nicola

Baeuerle, Patrick A.

Kufer, Peter

Wolf, Andreas

Klinger, Matthias http://orcid.org/0000-0001-7468-1951
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01209286 at ClinicalTrials.gov

Documents that mention this clinical trial

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
https://doi.org/10.1186/s40164-017-0074-5
Funding

Funding for this research was provided by:

Amgen Research (Munich) GmbH

Amgen Inc.
License Information

Text and Data Mining valid from 2017-05-18

Version of Record valid from 2017-05-18
More Information

Article History

Received: 29 March 2017

Accepted: 2 May 2017

First Online: 18 May 2017

Document is current